Encellin
San Francisco, US · 3 known investors
Encellin develops next-generation therapies for patients with chronic unmet clinical needs, using technology originating from Dr. Tejal Desai's laboratory at UCSF that combines micro and nanotechnologies with novel drug delivery approaches. The company focuses on therapeutic delivery platforms and cell-based treatments, particularly for diseases including diabetes and autoimmune conditions.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
TD
Tejal DesaiTechnology Expert, Founder
RM
Ronald MartellStrategic Advisor, Founder
Investors · 3
In the news
- Encellin: $9.9 Million Raised To Pioneer Living Medicine Platformspulse2.com · 2023
- Encellin raises about $10M for type 1 diabetes cell replacement therapy — Encellinencellin.com · 2023
- Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disordersbusinesswire.com · 2023
- Encellin Raises $9.9M in Fundingfinsmes.com · 2023
- Encellin - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Grace Wei’s Journey from Academia to Encellin Co-Founder and Entrepreneur — Encellinencellin.com · 2020